IMVT PEER ANALYSIS

Immunovant Inc — metric-by-metric comparison with peers and the industry median

IMVTImmunovant Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
IMVTIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
IMVT+130.8%TLX-29.5%CSL-48.2%MSB+27.6%
Year-to-Date (YTD)
IMVT+52.6%TLX+50.7%CSL-28.5%MSB-24.3%

Key Metric Comparison

P/E

Lower is better
IMVTTLXCSL29.44MSBMedian 17.91

ROE

Higher is better
IMVT-64.8%TLX-1.8%CSL7.7%MSB-11.3%Median -47.5%

Net Margin

Higher is better
IMVTTLX-0.9%CSL9.2%MSB-115.3%Median -125.7%

Revenue Growth

Higher is better
IMVT-100.0%TLX56.3%CSL4.8%MSB410.4%Median 5.1%

All Metrics

Valuation
MetricIMVTTLXCSLMSBInd. Median
P/E29.4417.91
P/B9.276.372.203.51
EV/EBITDA120.1410.2114.82
P/S3.242.6231.6110.89
Financial Health
MetricIMVTTLXCSLMSBInd. Median
Current Ratio9.091.432.575.90
Debt/Equity0.0%112.3%67.4%10.9%
NetDebt/EBITDA1.7913.132.221.15
Profitability
MetricIMVTTLXCSLMSBInd. Median
Net Margin-0.9%9.2%-115.3%-125.7%
ROE-64.8%-1.8%7.7%-11.3%-47.5%
ROA-58.3%-0.7%3.8%-8.6%-35.8%
EBITDA Margin3.0%32.8%-76.6%-105.8%
Growth + Dividend
MetricIMVTTLXCSLMSBInd. Median
Rev. Growth-100.0%56.3%4.8%410.4%5.1%
NI Growth-39.4%12.1%
Div. Yield2.5%0.0%0.2%
Payout103.1%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on IMVT

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.